Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today confirms that its shares are still eligible for the Equity Savings Plan, PEA-PME.
Genticel indeed still meets the PEA-PME eligibility criteria, which are specified in article D.221-113-5 of application decree n° 2014-283, dated March 4th, 2014:
- A total workforce of fewer than 5,000 employees;
- An annual turnover below ¤1.5 billion or total assets of less than ¤2 billion.
Therefore, Genticel shares can be included in PEA-PME accounts.
Financial calendar 2015
Each publication will be released after Euronext market closing.
|28 April 2015||Update on 2015 1st Quarter Business & Cash Position|
|11 June 2015||Annual Shareholders Meeting|
|28 July 2015||Update on 2015 2nd Quarter Business & Cash Position|
|21 September 2015||2015 Half-Year Results|
|28 October 2015||Update on 2015 3rd Quarter Business & Cash Position|
Upcoming Genticel meetings with investors
|25 April 2015||VFB Investor Happening - Brussels, Belgium|
|27 & 28 April 2015||Small & Midcap Event - Paris|
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.
Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.
In 2015, Genticel licensed its Vaxiclase technology to Serum Institute of India Ltd. (SIIL), the largest vaccine producer in the world, for use as a component in acellular multivalent combination vaccines including pertussis antigens.
Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most
Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.
Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.
For more information, please visit Genticel's website, www.genticel.com
|USA Investor Contact||INVESTOR CONTACT||PRESS CONTACT|
Chief Executive Officer
Tel.: +1 (212) 915 2577
Tel.: +33 (0)1 53 67 36 77
Tel.: +33 (0)1 53 67 36 90
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|GENTICEL||Euronext Paris||2.82 (c)||-13.23%||1 958 454|